perioperative management of glp-1 agonists Authors discuss recent evidence addressing risks in patients taking receptor agonist medications and propose a framework for management. Read the new Clinical Focus Review published in @_Anesthesiology: https://t.co/d909uqJh9c TIRZEPATIDE Mechanism of action Quantity:6 Months Optimizes Fat Metabolism

perioperative management of glp-1 agonists Authors discuss recent evidence addressing risks in patients taking receptor agonist medications and propose a framework for management. Read the new Clinical Focus Review published in @_Anesthesiology: https://t.co/d909uqJh9c TIRZEPATIDE Mechanism of action Quantity:6 Months Optimizes Fat Metabolism

TIRZEPATIDE Mechanism of action of tirzepatide GIP = glucose-dependent insulinotropic polypeptide; GLP-1 = glucagon-like peptide 1; LDL = low-density lipoprotein; HR = heart rate.

The international clinical development of efpeglenatide was stopped, despite being the only exendin derivative that, in a (terminated) phase 3 RCT, showed kidney benefit [HR 0.68 (95% CI 0.57–0.79)] and a reduction in the primary MACE outcome in T2DM patients with a history of CVD or CKD plus at least one other cardiovascular risk factor [57]

Optimizes Fat Metabolism

Quantity:6 Months

Will insurance cover prescription weight loss medication